| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Organ Transplantation | 59 | 2023 | 1139 | 8.950 |
Why?
|
| Transplantation, Heterologous | 61 | 2023 | 2382 | 6.220 |
Why?
|
| Immunocompromised Host | 30 | 2023 | 847 | 4.160 |
Why?
|
| Cytomegalovirus Infections | 28 | 2023 | 820 | 3.130 |
Why?
|
| Tissue Donors | 26 | 2023 | 2240 | 2.820 |
Why?
|
| Pneumonia, Pneumocystis | 20 | 2023 | 249 | 2.710 |
Why?
|
| Cytomegalovirus | 18 | 2023 | 732 | 2.660 |
Why?
|
| Transplantation | 14 | 2013 | 217 | 2.480 |
Why?
|
| Kidney Transplantation | 36 | 2020 | 4251 | 2.270 |
Why?
|
| Virus Diseases | 10 | 2023 | 711 | 2.260 |
Why?
|
| Tissue and Organ Procurement | 12 | 2018 | 896 | 2.230 |
Why?
|
| Opportunistic Infections | 10 | 2014 | 389 | 2.220 |
Why?
|
| Pneumocystis carinii | 4 | 2023 | 74 | 1.950 |
Why?
|
| Retroviridae Infections | 8 | 2018 | 151 | 1.910 |
Why?
|
| Endogenous Retroviruses | 11 | 2020 | 112 | 1.880 |
Why?
|
| Zoonoses | 12 | 2023 | 185 | 1.830 |
Why?
|
| Communicable Diseases | 12 | 2023 | 880 | 1.820 |
Why?
|
| Donor Selection | 5 | 2014 | 201 | 1.820 |
Why?
|
| Swine | 57 | 2023 | 5917 | 1.660 |
Why?
|
| Liver Transplantation | 20 | 2020 | 2119 | 1.620 |
Why?
|
| Immunosuppressive Agents | 23 | 2023 | 4149 | 1.470 |
Why?
|
| Graft Rejection | 26 | 2021 | 4397 | 1.430 |
Why?
|
| Antifungal Agents | 17 | 2016 | 730 | 1.410 |
Why?
|
| Transplants | 6 | 2016 | 209 | 1.410 |
Why?
|
| Cryptococcosis | 5 | 2014 | 101 | 1.340 |
Why?
|
| Pneumocystis Infections | 5 | 2019 | 10 | 1.330 |
Why?
|
| Disease Transmission, Infectious | 9 | 2017 | 547 | 1.250 |
Why?
|
| Pneumocystis | 14 | 2001 | 57 | 1.170 |
Why?
|
| Hepatitis C | 8 | 2022 | 1591 | 1.170 |
Why?
|
| Mycoses | 8 | 2014 | 376 | 1.120 |
Why?
|
| Ganciclovir | 10 | 2007 | 258 | 1.010 |
Why?
|
| Infection Control | 4 | 2019 | 966 | 0.980 |
Why?
|
| Papio | 23 | 2018 | 656 | 0.950 |
Why?
|
| Central Nervous System Infections | 2 | 2014 | 56 | 0.940 |
Why?
|
| Herpesviridae Infections | 4 | 2013 | 277 | 0.890 |
Why?
|
| Transplantation Immunology | 10 | 2013 | 546 | 0.810 |
Why?
|
| Antiviral Agents | 18 | 2020 | 2987 | 0.790 |
Why?
|
| Graft Survival | 14 | 2020 | 3737 | 0.780 |
Why?
|
| Retroviridae | 5 | 2010 | 914 | 0.760 |
Why?
|
| Swine, Miniature | 15 | 2012 | 961 | 0.760 |
Why?
|
| Parasites | 1 | 2023 | 163 | 0.760 |
Why?
|
| DNA, Viral | 10 | 2018 | 2225 | 0.720 |
Why?
|
| Tissue Transplantation | 2 | 2012 | 130 | 0.720 |
Why?
|
| Nucleic Acids | 1 | 2022 | 182 | 0.710 |
Why?
|
| Transplantation, Homologous | 11 | 2016 | 4776 | 0.690 |
Why?
|
| Heart Transplantation | 14 | 2023 | 3110 | 0.670 |
Why?
|
| Epstein-Barr Virus Infections | 4 | 2014 | 570 | 0.660 |
Why?
|
| Postoperative Complications | 19 | 2019 | 15295 | 0.650 |
Why?
|
| Anti-Infective Agents | 6 | 2012 | 972 | 0.640 |
Why?
|
| Serologic Tests | 2 | 2017 | 374 | 0.640 |
Why?
|
| Varicellovirus | 2 | 2008 | 7 | 0.640 |
Why?
|
| Humans | 202 | 2023 | 744343 | 0.610 |
Why?
|
| Polyomavirus Infections | 4 | 2007 | 197 | 0.610 |
Why?
|
| Coronavirus | 1 | 2020 | 158 | 0.600 |
Why?
|
| Viral Load | 5 | 2020 | 3299 | 0.600 |
Why?
|
| BK Virus | 3 | 2003 | 129 | 0.600 |
Why?
|
| Pneumonia, Viral | 5 | 2020 | 3240 | 0.590 |
Why?
|
| Advisory Committees | 2 | 2021 | 775 | 0.570 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 2 | 2010 | 459 | 0.530 |
Why?
|
| Immune System Diseases | 3 | 2015 | 262 | 0.530 |
Why?
|
| Laboratories | 2 | 2014 | 463 | 0.520 |
Why?
|
| Coronavirus Infections | 4 | 2020 | 3133 | 0.520 |
Why?
|
| Tumor Virus Infections | 3 | 2003 | 452 | 0.520 |
Why?
|
| Gammaherpesvirinae | 3 | 2005 | 27 | 0.510 |
Why?
|
| Invasive Pulmonary Aspergillosis | 1 | 2014 | 15 | 0.510 |
Why?
|
| Virus Replication | 10 | 2013 | 2534 | 0.500 |
Why?
|
| AIDS-Related Opportunistic Infections | 4 | 2009 | 657 | 0.500 |
Why?
|
| Antigens, Fungal | 1 | 2014 | 70 | 0.490 |
Why?
|
| Mannans | 1 | 2014 | 63 | 0.490 |
Why?
|
| Animals | 102 | 2023 | 168757 | 0.490 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2014 | 66 | 0.480 |
Why?
|
| Immunity, Innate | 4 | 2016 | 2958 | 0.460 |
Why?
|
| Galactosyltransferases | 7 | 2014 | 263 | 0.450 |
Why?
|
| Adaptive Immunity | 2 | 2016 | 713 | 0.450 |
Why?
|
| Respiratory Tract Infections | 1 | 2020 | 961 | 0.450 |
Why?
|
| Vancomycin Resistance | 2 | 2003 | 128 | 0.440 |
Why?
|
| Immunity, Cellular | 2 | 2016 | 1607 | 0.430 |
Why?
|
| Dyspnea | 1 | 2020 | 1303 | 0.430 |
Why?
|
| Pneumococcal Infections | 1 | 2017 | 497 | 0.420 |
Why?
|
| Herpesviridae | 1 | 2013 | 109 | 0.420 |
Why?
|
| Cryptococcus neoformans | 2 | 2009 | 119 | 0.400 |
Why?
|
| Lymphoproliferative Disorders | 5 | 2007 | 523 | 0.400 |
Why?
|
| Virus Activation | 3 | 2004 | 319 | 0.400 |
Why?
|
| Streptococcus pneumoniae | 1 | 2017 | 714 | 0.400 |
Why?
|
| Polymerase Chain Reaction | 8 | 2023 | 6171 | 0.400 |
Why?
|
| Probiotics | 1 | 2015 | 351 | 0.390 |
Why?
|
| Meningitis, Cryptococcal | 2 | 2009 | 63 | 0.390 |
Why?
|
| Risk Factors | 37 | 2018 | 72290 | 0.390 |
Why?
|
| Pandemics | 7 | 2021 | 8388 | 0.380 |
Why?
|
| Hepacivirus | 6 | 2022 | 1379 | 0.380 |
Why?
|
| Gram-Positive Bacterial Infections | 2 | 2003 | 341 | 0.380 |
Why?
|
| Acquired Immunodeficiency Syndrome | 4 | 2016 | 2232 | 0.380 |
Why?
|
| Kidney | 10 | 2018 | 7186 | 0.370 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2023 | 3597 | 0.370 |
Why?
|
| Expert Testimony | 2 | 2023 | 356 | 0.360 |
Why?
|
| Kidney Diseases | 2 | 2017 | 2149 | 0.360 |
Why?
|
| Aspergillosis | 6 | 2016 | 235 | 0.360 |
Why?
|
| Naphthoquinones | 4 | 2004 | 77 | 0.360 |
Why?
|
| Killer Cells, Natural | 5 | 2012 | 2133 | 0.350 |
Why?
|
| Antibodies, Neoplasm | 1 | 2011 | 286 | 0.350 |
Why?
|
| Bacterial Infections | 2 | 2014 | 1401 | 0.350 |
Why?
|
| Practice Guidelines as Topic | 7 | 2020 | 7279 | 0.340 |
Why?
|
| Immune System | 1 | 2015 | 805 | 0.340 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 9 | 2019 | 5442 | 0.340 |
Why?
|
| Influenza, Human | 2 | 2010 | 1479 | 0.330 |
Why?
|
| Mycobacterium tuberculosis | 2 | 2019 | 1832 | 0.320 |
Why?
|
| Bone Marrow Transplantation | 11 | 2015 | 2765 | 0.320 |
Why?
|
| Tuberculosis | 2 | 2019 | 1912 | 0.320 |
Why?
|
| Herpesvirus 4, Human | 2 | 2014 | 1041 | 0.310 |
Why?
|
| Tissue Banks | 1 | 2008 | 184 | 0.310 |
Why?
|
| Hepatitis B virus | 3 | 2022 | 513 | 0.310 |
Why?
|
| Chimerism | 1 | 2008 | 158 | 0.300 |
Why?
|
| Quality Assurance, Health Care | 1 | 2018 | 2212 | 0.300 |
Why?
|
| Registries | 4 | 2018 | 8089 | 0.300 |
Why?
|
| Mammary Glands, Animal | 3 | 2000 | 276 | 0.300 |
Why?
|
| Candidiasis | 5 | 2017 | 366 | 0.290 |
Why?
|
| Genome, Viral | 2 | 2010 | 667 | 0.290 |
Why?
|
| HIV Infections | 6 | 2022 | 16718 | 0.290 |
Why?
|
| Drug Resistance, Viral | 1 | 2011 | 820 | 0.280 |
Why?
|
| Microbiological Techniques | 3 | 2019 | 102 | 0.280 |
Why?
|
| Thymus Gland | 8 | 2009 | 1267 | 0.280 |
Why?
|
| Pseudomonas Infections | 2 | 2001 | 613 | 0.270 |
Why?
|
| Bioterrorism | 2 | 2003 | 143 | 0.270 |
Why?
|
| Candida | 6 | 2017 | 172 | 0.270 |
Why?
|
| Animals, Genetically Modified | 9 | 2017 | 1549 | 0.260 |
Why?
|
| Antilymphocyte Serum | 6 | 2011 | 492 | 0.250 |
Why?
|
| Informed Consent | 3 | 2008 | 995 | 0.250 |
Why?
|
| Disseminated Intravascular Coagulation | 2 | 2004 | 188 | 0.250 |
Why?
|
| Anti-Bacterial Agents | 5 | 2019 | 7181 | 0.250 |
Why?
|
| Weaning | 1 | 2005 | 105 | 0.250 |
Why?
|
| Mycobacterium avium Complex | 1 | 2004 | 60 | 0.240 |
Why?
|
| Pilonidal Sinus | 1 | 2004 | 16 | 0.240 |
Why?
|
| Liver Failure | 1 | 2006 | 241 | 0.240 |
Why?
|
| Sus scrofa | 3 | 2014 | 437 | 0.240 |
Why?
|
| Hepatitis B | 3 | 2017 | 695 | 0.240 |
Why?
|
| T-Lymphocytes | 10 | 2016 | 10180 | 0.240 |
Why?
|
| Homeostasis | 1 | 2015 | 3340 | 0.230 |
Why?
|
| Immunotherapy | 1 | 2019 | 4445 | 0.230 |
Why?
|
| Swine Diseases | 2 | 2001 | 73 | 0.230 |
Why?
|
| Mycobacterium Infections | 1 | 2004 | 119 | 0.230 |
Why?
|
| Hepatitis C, Chronic | 3 | 2020 | 1031 | 0.230 |
Why?
|
| Acyclovir | 3 | 2000 | 272 | 0.230 |
Why?
|
| Smallpox | 1 | 2003 | 45 | 0.230 |
Why?
|
| Lymphocytic choriomeningitis virus | 3 | 2009 | 168 | 0.220 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2008 | 738 | 0.220 |
Why?
|
| Oxazolidinones | 1 | 2003 | 96 | 0.220 |
Why?
|
| Smallpox Vaccine | 1 | 2003 | 80 | 0.220 |
Why?
|
| Lung Diseases, Fungal | 1 | 2003 | 122 | 0.220 |
Why?
|
| Disease Susceptibility | 2 | 2020 | 1782 | 0.220 |
Why?
|
| Enterococcus faecium | 1 | 2003 | 102 | 0.220 |
Why?
|
| Fever | 4 | 2020 | 1616 | 0.210 |
Why?
|
| Foscarnet | 1 | 2002 | 38 | 0.210 |
Why?
|
| Amphotericin B | 6 | 2016 | 137 | 0.210 |
Why?
|
| Transplantation Tolerance | 5 | 2014 | 617 | 0.210 |
Why?
|
| Enterococcus | 1 | 2003 | 157 | 0.210 |
Why?
|
| Recombination, Genetic | 2 | 2006 | 1586 | 0.210 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2003 | 137 | 0.210 |
Why?
|
| Disease Outbreaks | 2 | 2009 | 1772 | 0.210 |
Why?
|
| Abscess | 3 | 2002 | 607 | 0.210 |
Why?
|
| Nephritis | 1 | 2003 | 159 | 0.200 |
Why?
|
| Acetamides | 1 | 2003 | 249 | 0.200 |
Why?
|
| Islets of Langerhans Transplantation | 2 | 2017 | 745 | 0.200 |
Why?
|
| Cytosine | 1 | 2003 | 216 | 0.200 |
Why?
|
| Fallopian Tube Diseases | 1 | 2001 | 62 | 0.200 |
Why?
|
| Vaccination | 3 | 2022 | 3278 | 0.200 |
Why?
|
| Nucleic Acid Amplification Techniques | 2 | 2017 | 323 | 0.190 |
Why?
|
| Listeriosis | 1 | 2002 | 149 | 0.190 |
Why?
|
| Papio hamadryas | 2 | 2018 | 29 | 0.190 |
Why?
|
| Lymphocyte Transfusion | 2 | 2016 | 236 | 0.190 |
Why?
|
| Leukemia, Myeloid | 1 | 2004 | 707 | 0.190 |
Why?
|
| Mass Screening | 3 | 2011 | 5255 | 0.190 |
Why?
|
| Lymphocytes | 2 | 2008 | 2617 | 0.190 |
Why?
|
| Peptides, Cyclic | 2 | 2006 | 400 | 0.190 |
Why?
|
| Fungi | 5 | 2009 | 327 | 0.190 |
Why?
|
| Spleen | 1 | 2007 | 2362 | 0.190 |
Why?
|
| Audiology | 1 | 2020 | 20 | 0.190 |
Why?
|
| Arenaviridae Infections | 3 | 2009 | 51 | 0.190 |
Why?
|
| Ovarian Diseases | 1 | 2001 | 139 | 0.180 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2020 | 226 | 0.180 |
Why?
|
| Lung Diseases | 1 | 2010 | 1886 | 0.180 |
Why?
|
| Proteolipids | 2 | 1998 | 117 | 0.180 |
Why?
|
| Communicable Disease Control | 3 | 2020 | 857 | 0.180 |
Why?
|
| Inflammation | 1 | 2019 | 10638 | 0.170 |
Why?
|
| Europe | 2 | 2023 | 3339 | 0.170 |
Why?
|
| Immune Tolerance | 8 | 2009 | 2258 | 0.170 |
Why?
|
| Glucocorticoids | 2 | 2023 | 2107 | 0.170 |
Why?
|
| Pulmonary Surfactants | 2 | 1998 | 162 | 0.170 |
Why?
|
| Caspases | 1 | 2002 | 928 | 0.170 |
Why?
|
| Minority Groups | 1 | 2006 | 1223 | 0.160 |
Why?
|
| Fungemia | 2 | 2009 | 53 | 0.160 |
Why?
|
| Echinocandins | 5 | 2016 | 45 | 0.160 |
Why?
|
| Exanthema | 1 | 2023 | 501 | 0.160 |
Why?
|
| Environmental Health | 1 | 2000 | 278 | 0.160 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2000 | 419 | 0.160 |
Why?
|
| Fungal Proteins | 2 | 2002 | 912 | 0.160 |
Why?
|
| Hydroxyestrones | 2 | 1995 | 18 | 0.160 |
Why?
|
| Atovaquone | 4 | 2004 | 58 | 0.150 |
Why?
|
| New York | 1 | 2020 | 886 | 0.150 |
Why?
|
| Immunity, Humoral | 1 | 2022 | 598 | 0.150 |
Why?
|
| Trust | 1 | 2022 | 505 | 0.150 |
Why?
|
| Immunization | 2 | 2021 | 1256 | 0.150 |
Why?
|
| Wound Infection | 1 | 1999 | 242 | 0.150 |
Why?
|
| Male | 51 | 2023 | 350118 | 0.150 |
Why?
|
| Pentamidine | 3 | 2004 | 45 | 0.140 |
Why?
|
| Community-Acquired Infections | 1 | 2020 | 465 | 0.140 |
Why?
|
| Antibodies, Monoclonal | 3 | 2011 | 9274 | 0.140 |
Why?
|
| Pneumonia, Bacterial | 1 | 1999 | 316 | 0.140 |
Why?
|
| Heart | 2 | 2020 | 4467 | 0.140 |
Why?
|
| Pneumonia | 4 | 2002 | 2133 | 0.140 |
Why?
|
| Adult | 38 | 2021 | 214055 | 0.140 |
Why?
|
| Protozoan Infections | 1 | 1995 | 39 | 0.140 |
Why?
|
| Virus Inactivation | 1 | 2015 | 20 | 0.140 |
Why?
|
| Human Experimentation | 1 | 1996 | 127 | 0.130 |
Why?
|
| Diagnosis, Differential | 6 | 2020 | 12959 | 0.130 |
Why?
|
| Lymphocyte Depletion | 3 | 2016 | 608 | 0.130 |
Why?
|
| United States | 15 | 2023 | 69872 | 0.130 |
Why?
|
| Primates | 2 | 2014 | 545 | 0.130 |
Why?
|
| Societies, Medical | 5 | 2020 | 3743 | 0.130 |
Why?
|
| Transplantation Conditioning | 5 | 2019 | 1598 | 0.130 |
Why?
|
| Estradiol | 4 | 1995 | 2020 | 0.130 |
Why?
|
| Risk Assessment | 7 | 2023 | 23338 | 0.130 |
Why?
|
| Thrombocytopenia | 1 | 2003 | 1179 | 0.130 |
Why?
|
| False Positive Reactions | 1 | 2017 | 981 | 0.130 |
Why?
|
| Blood Coagulation Factors | 1 | 2017 | 355 | 0.130 |
Why?
|
| Research Report | 1 | 2018 | 355 | 0.130 |
Why?
|
| Phytosterols | 1 | 1994 | 64 | 0.120 |
Why?
|
| Azoles | 3 | 2016 | 20 | 0.120 |
Why?
|
| Middle Aged | 35 | 2023 | 213383 | 0.120 |
Why?
|
| Colitis, Ulcerative | 1 | 2006 | 1912 | 0.120 |
Why?
|
| Respiratory Insufficiency | 1 | 2023 | 1199 | 0.120 |
Why?
|
| Aged | 27 | 2023 | 163280 | 0.120 |
Why?
|
| Blood Donors | 1 | 2016 | 355 | 0.120 |
Why?
|
| Aspergillus fumigatus | 2 | 2008 | 150 | 0.120 |
Why?
|
| Environmental Monitoring | 1 | 2000 | 1414 | 0.120 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2017 | 3870 | 0.120 |
Why?
|
| International Agencies | 1 | 2014 | 240 | 0.120 |
Why?
|
| HIV | 2 | 2017 | 1604 | 0.120 |
Why?
|
| Indium Radioisotopes | 2 | 1991 | 118 | 0.120 |
Why?
|
| Female | 53 | 2023 | 380194 | 0.120 |
Why?
|
| Neoplasms | 6 | 2019 | 21683 | 0.120 |
Why?
|
| Treatment Outcome | 14 | 2022 | 63114 | 0.120 |
Why?
|
| Medical Tourism | 1 | 2014 | 57 | 0.120 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2014 | 224 | 0.110 |
Why?
|
| Hepatitis B Antibodies | 1 | 2014 | 159 | 0.110 |
Why?
|
| Bile Acids and Salts | 1 | 1995 | 367 | 0.110 |
Why?
|
| Galactose | 1 | 2014 | 306 | 0.110 |
Why?
|
| Immunoassay | 1 | 2017 | 752 | 0.110 |
Why?
|
| Pneumococcal Vaccines | 1 | 2017 | 391 | 0.110 |
Why?
|
| Transplantation Chimera | 4 | 2016 | 612 | 0.110 |
Why?
|
| Motivation | 1 | 2023 | 1971 | 0.110 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 1993 | 87 | 0.110 |
Why?
|
| Otolaryngology | 1 | 2020 | 645 | 0.110 |
Why?
|
| Disaccharides | 3 | 2004 | 171 | 0.110 |
Why?
|
| Lung Transplantation | 2 | 2017 | 1153 | 0.110 |
Why?
|
| Peptides | 2 | 2023 | 4409 | 0.110 |
Why?
|
| Diet, Fat-Restricted | 1 | 1995 | 320 | 0.110 |
Why?
|
| Congresses as Topic | 1 | 2017 | 764 | 0.110 |
Why?
|
| Fatal Outcome | 4 | 2017 | 1850 | 0.110 |
Why?
|
| Trisaccharides | 2 | 2005 | 50 | 0.110 |
Why?
|
| Retrospective Studies | 7 | 2023 | 77449 | 0.110 |
Why?
|
| Guanine | 1 | 2014 | 274 | 0.110 |
Why?
|
| Lamivudine | 1 | 2014 | 342 | 0.110 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2013 | 639 | 0.110 |
Why?
|
| Postmenopause | 1 | 2001 | 2461 | 0.110 |
Why?
|
| Case Management | 1 | 2014 | 286 | 0.100 |
Why?
|
| Estriol | 2 | 1995 | 53 | 0.100 |
Why?
|
| Pseudomonas aeruginosa | 1 | 1999 | 1219 | 0.100 |
Why?
|
| Gene Targeting | 1 | 2015 | 880 | 0.100 |
Why?
|
| Bone Marrow Cells | 3 | 2015 | 2513 | 0.100 |
Why?
|
| Kidney Failure, Chronic | 2 | 2019 | 2538 | 0.100 |
Why?
|
| Sputum | 1 | 1994 | 476 | 0.100 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2012 | 227 | 0.100 |
Why?
|
| Mycobacterium kansasii | 1 | 2011 | 11 | 0.100 |
Why?
|
| Human T-lymphotropic virus 2 | 1 | 2011 | 10 | 0.100 |
Why?
|
| Drug Interactions | 2 | 2010 | 1460 | 0.100 |
Why?
|
| DNA Primers | 3 | 2012 | 2892 | 0.100 |
Why?
|
| Injections, Intravenous | 4 | 2000 | 1420 | 0.100 |
Why?
|
| Cross Infection | 3 | 2009 | 1416 | 0.100 |
Why?
|
| Antibodies, Bacterial | 1 | 2017 | 1470 | 0.100 |
Why?
|
| Antibody Specificity | 2 | 2005 | 1095 | 0.100 |
Why?
|
| Women's Health | 1 | 2000 | 2034 | 0.100 |
Why?
|
| Species Specificity | 4 | 2004 | 2478 | 0.100 |
Why?
|
| Pentetic Acid | 1 | 1991 | 213 | 0.100 |
Why?
|
| Reference Standards | 1 | 2014 | 1025 | 0.100 |
Why?
|
| Liver Abscess | 1 | 2011 | 82 | 0.090 |
Why?
|
| Antibodies | 4 | 2014 | 2460 | 0.090 |
Why?
|
| Comorbidity | 2 | 2020 | 10388 | 0.090 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2019 | 1270 | 0.090 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 3176 | 0.090 |
Why?
|
| Incidence | 5 | 2015 | 20947 | 0.090 |
Why?
|
| Human T-lymphotropic virus 1 | 1 | 2011 | 140 | 0.090 |
Why?
|
| Molecular Sequence Data | 7 | 2015 | 18111 | 0.090 |
Why?
|
| Neutropenia | 2 | 2007 | 895 | 0.090 |
Why?
|
| Rats, Inbred Strains | 6 | 1991 | 2186 | 0.090 |
Why?
|
| Sarcoma, Kaposi | 1 | 2013 | 370 | 0.090 |
Why?
|
| Central Nervous System Fungal Infections | 1 | 2009 | 25 | 0.090 |
Why?
|
| Life Cycle Stages | 1 | 2010 | 160 | 0.090 |
Why?
|
| Respiration, Artificial | 1 | 2020 | 2569 | 0.090 |
Why?
|
| Sepsis | 2 | 1999 | 2593 | 0.090 |
Why?
|
| Amino Acid Sequence | 6 | 2006 | 13815 | 0.090 |
Why?
|
| Latent Tuberculosis | 1 | 2012 | 225 | 0.080 |
Why?
|
| Thymectomy | 2 | 2002 | 191 | 0.080 |
Why?
|
| Angioplasty, Balloon | 3 | 1988 | 653 | 0.080 |
Why?
|
| Rats | 14 | 2001 | 24260 | 0.080 |
Why?
|
| GPI-Linked Proteins | 1 | 2010 | 434 | 0.080 |
Why?
|
| Reperfusion Injury | 1 | 2016 | 1026 | 0.080 |
Why?
|
| Hematologic Diseases | 1 | 2012 | 498 | 0.080 |
Why?
|
| Base Sequence | 4 | 2015 | 12797 | 0.080 |
Why?
|
| Radiography | 1 | 2020 | 7023 | 0.080 |
Why?
|
| Antibodies, Heterophile | 2 | 1999 | 126 | 0.080 |
Why?
|
| Disease Management | 1 | 2019 | 2459 | 0.080 |
Why?
|
| RNA, Messenger | 4 | 2008 | 13033 | 0.080 |
Why?
|
| Adenine | 1 | 2014 | 936 | 0.080 |
Why?
|
| Hematologic Neoplasms | 2 | 2019 | 1832 | 0.080 |
Why?
|
| Dapsone | 2 | 1998 | 54 | 0.080 |
Why?
|
| Burns | 1 | 1999 | 1815 | 0.080 |
Why?
|
| Breast | 2 | 1995 | 1969 | 0.080 |
Why?
|
| Cell Line | 6 | 2015 | 15997 | 0.080 |
Why?
|
| Health Care Costs | 2 | 2014 | 3209 | 0.080 |
Why?
|
| Clindamycin | 2 | 1998 | 139 | 0.080 |
Why?
|
| Graft vs Host Disease | 2 | 2016 | 2957 | 0.080 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2009 | 310 | 0.080 |
Why?
|
| RNA, Ribosomal | 1 | 1989 | 246 | 0.080 |
Why?
|
| Aneurysm, Infected | 1 | 2008 | 85 | 0.080 |
Why?
|
| HIV-1 | 2 | 2003 | 6939 | 0.080 |
Why?
|
| Risk | 5 | 2007 | 9687 | 0.080 |
Why?
|
| Genes, pol | 2 | 2015 | 51 | 0.070 |
Why?
|
| Antigens, Protozoan | 2 | 1989 | 322 | 0.070 |
Why?
|
| Extracellular Matrix Proteins | 1 | 1991 | 849 | 0.070 |
Why?
|
| Orthomyxoviridae Infections | 1 | 2009 | 248 | 0.070 |
Why?
|
| Disease Models, Animal | 10 | 2017 | 18029 | 0.070 |
Why?
|
| Chemoprevention | 2 | 2012 | 319 | 0.070 |
Why?
|
| Cyclosporine | 4 | 2016 | 786 | 0.070 |
Why?
|
| Fluconazole | 2 | 2009 | 146 | 0.070 |
Why?
|
| Cost-Benefit Analysis | 3 | 2014 | 5391 | 0.070 |
Why?
|
| Coccidioides | 1 | 2006 | 17 | 0.070 |
Why?
|
| Infectious Disease Medicine | 2 | 2016 | 46 | 0.070 |
Why?
|
| Th17 Cells | 1 | 2012 | 766 | 0.070 |
Why?
|
| Sulfamethoxazole | 2 | 2004 | 53 | 0.070 |
Why?
|
| B-Lymphocytes | 5 | 2012 | 4665 | 0.070 |
Why?
|
| Professional Misconduct | 1 | 2006 | 73 | 0.070 |
Why?
|
| Spinal Puncture | 1 | 2008 | 281 | 0.070 |
Why?
|
| Analgesics, Opioid | 1 | 2022 | 3674 | 0.070 |
Why?
|
| Environmental Exposure | 1 | 2000 | 4234 | 0.070 |
Why?
|
| Whole-Body Irradiation | 3 | 2016 | 449 | 0.070 |
Why?
|
| Confusion | 1 | 2008 | 275 | 0.070 |
Why?
|
| World Health Organization | 1 | 2012 | 1318 | 0.070 |
Why?
|
| Coccidioidomycosis | 1 | 2006 | 36 | 0.070 |
Why?
|
| Immunologic Memory | 1 | 2012 | 1348 | 0.070 |
Why?
|
| Trimethoprim | 2 | 2004 | 91 | 0.070 |
Why?
|
| DNA, Complementary | 2 | 2000 | 2050 | 0.070 |
Why?
|
| Gene Products, env | 1 | 2006 | 263 | 0.070 |
Why?
|
| Lymphocytic Choriomeningitis | 1 | 2006 | 132 | 0.070 |
Why?
|
| Puromycin Aminonucleoside | 1 | 1985 | 12 | 0.070 |
Why?
|
| Puromycin | 1 | 1985 | 44 | 0.070 |
Why?
|
| Menstrual Cycle | 3 | 1995 | 551 | 0.070 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1995 | 2942 | 0.070 |
Why?
|
| Biological Assay | 1 | 2008 | 652 | 0.060 |
Why?
|
| Proviruses | 3 | 2007 | 318 | 0.060 |
Why?
|
| Clinical Trials as Topic | 3 | 2020 | 7913 | 0.060 |
Why?
|
| Basal Ganglia | 1 | 2008 | 546 | 0.060 |
Why?
|
| Diagnostic Imaging | 1 | 2019 | 3507 | 0.060 |
Why?
|
| Immunoglobulin G | 5 | 1998 | 4560 | 0.060 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 2000 | 2839 | 0.060 |
Why?
|
| Autoimmunity | 1 | 2012 | 1349 | 0.060 |
Why?
|
| Ethics, Research | 1 | 2006 | 191 | 0.060 |
Why?
|
| Aspergillus | 3 | 2010 | 85 | 0.060 |
Why?
|
| Trichuriasis | 1 | 1984 | 24 | 0.060 |
Why?
|
| Cell Transplantation | 2 | 2004 | 477 | 0.060 |
Why?
|
| Metacarpus | 1 | 1984 | 35 | 0.060 |
Why?
|
| Intestinal Diseases, Parasitic | 1 | 1984 | 66 | 0.060 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2002 | 1877 | 0.060 |
Why?
|
| Acute Disease | 2 | 2005 | 7149 | 0.060 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 1999 | 1475 | 0.060 |
Why?
|
| Drug Therapy, Combination | 4 | 2005 | 6489 | 0.060 |
Why?
|
| Lipids | 2 | 1994 | 3305 | 0.060 |
Why?
|
| Antitubercular Agents | 1 | 2012 | 1320 | 0.060 |
Why?
|
| Time Factors | 13 | 2010 | 40075 | 0.060 |
Why?
|
| Radiography, Thoracic | 1 | 2010 | 1265 | 0.060 |
Why?
|
| Lung | 5 | 2006 | 9856 | 0.060 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2003 | 1873 | 0.060 |
Why?
|
| Child | 10 | 2021 | 77709 | 0.060 |
Why?
|
| Open Reading Frames | 1 | 2007 | 810 | 0.060 |
Why?
|
| Conserved Sequence | 1 | 2007 | 1202 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2004 | 11524 | 0.060 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 1995 | 2020 | 0.060 |
Why?
|
| Blood Cell Count | 1 | 2004 | 403 | 0.060 |
Why?
|
| Aneurysm, Ruptured | 1 | 2008 | 452 | 0.060 |
Why?
|
| Survival Rate | 4 | 2017 | 12788 | 0.060 |
Why?
|
| Skin Ulcer | 1 | 2004 | 120 | 0.050 |
Why?
|
| Macrophages, Alveolar | 2 | 1998 | 407 | 0.050 |
Why?
|
| Bacteria | 1 | 1994 | 2114 | 0.050 |
Why?
|
| Risk-Taking | 1 | 2008 | 986 | 0.050 |
Why?
|
| Deoxycholic Acid | 2 | 2009 | 54 | 0.050 |
Why?
|
| Evaluation Studies as Topic | 2 | 1996 | 1681 | 0.050 |
Why?
|
| Death | 1 | 2007 | 678 | 0.050 |
Why?
|
| Indians, North American | 1 | 2006 | 355 | 0.050 |
Why?
|
| HLA Antigens | 1 | 2008 | 1381 | 0.050 |
Why?
|
| Forecasting | 3 | 2002 | 2951 | 0.050 |
Why?
|
| Colonic Diseases | 1 | 1984 | 202 | 0.050 |
Why?
|
| Inclusion Bodies, Viral | 1 | 2002 | 45 | 0.050 |
Why?
|
| Disclosure | 1 | 2008 | 736 | 0.050 |
Why?
|
| Caspases, Initiator | 1 | 2002 | 32 | 0.050 |
Why?
|
| Triazoles | 2 | 2009 | 911 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2011 | 3772 | 0.050 |
Why?
|
| Intestinal Perforation | 1 | 1984 | 253 | 0.050 |
Why?
|
| Nucleosides | 1 | 2002 | 138 | 0.050 |
Why?
|
| Electronic Health Records | 2 | 2020 | 4468 | 0.050 |
Why?
|
| Gene Dosage | 2 | 2015 | 1252 | 0.050 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 2002 | 248 | 0.050 |
Why?
|
| Kidney Glomerulus | 1 | 1985 | 697 | 0.050 |
Why?
|
| CD40 Ligand | 1 | 2004 | 526 | 0.050 |
Why?
|
| Mice | 12 | 2009 | 81183 | 0.050 |
Why?
|
| Candida glabrata | 1 | 2002 | 34 | 0.050 |
Why?
|
| Mammary Neoplasms, Experimental | 2 | 2000 | 520 | 0.050 |
Why?
|
| Platelet Count | 1 | 2004 | 781 | 0.050 |
Why?
|
| Organophosphorus Compounds | 1 | 2003 | 215 | 0.050 |
Why?
|
| Pyrimidines | 3 | 2009 | 2942 | 0.050 |
Why?
|
| Coronary Disease | 4 | 2009 | 6077 | 0.050 |
Why?
|
| Models, Animal | 3 | 2005 | 2171 | 0.050 |
Why?
|
| Quality Improvement | 1 | 2017 | 3749 | 0.050 |
Why?
|
| Dendritic Cells | 1 | 2012 | 2725 | 0.050 |
Why?
|
| Steroid 16-alpha-Hydroxylase | 3 | 1986 | 12 | 0.050 |
Why?
|
| Vaccinia virus | 1 | 2003 | 349 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2016 | 3336 | 0.050 |
Why?
|
| Fibrinogen | 1 | 2004 | 894 | 0.050 |
Why?
|
| Treatment Failure | 2 | 2004 | 2618 | 0.050 |
Why?
|
| Mice, Inbred DBA | 1 | 2002 | 642 | 0.050 |
Why?
|
| Histocompatibility Testing | 4 | 2008 | 741 | 0.050 |
Why?
|
| Naloxone | 2 | 1983 | 367 | 0.050 |
Why?
|
| RNA, Viral | 2 | 2007 | 2902 | 0.050 |
Why?
|
| Genes, Viral | 1 | 2002 | 718 | 0.050 |
Why?
|
| Gene Library | 2 | 2007 | 1074 | 0.050 |
Why?
|
| Administration, Oral | 4 | 2000 | 3913 | 0.050 |
Why?
|
| Interleukin-18 | 1 | 2002 | 249 | 0.050 |
Why?
|
| Mandatory Testing | 1 | 2020 | 23 | 0.050 |
Why?
|
| Intestinal Obstruction | 1 | 1984 | 424 | 0.050 |
Why?
|
| Creatinine | 3 | 2014 | 1919 | 0.050 |
Why?
|
| Body Burden | 1 | 2000 | 158 | 0.050 |
Why?
|
| Membrane Glycoproteins | 2 | 2010 | 3768 | 0.050 |
Why?
|
| Pulmonary Surfactant-Associated Proteins | 2 | 1998 | 19 | 0.050 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2000 | 106 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 6 | 2009 | 21827 | 0.050 |
Why?
|
| Listeria monocytogenes | 1 | 2002 | 250 | 0.050 |
Why?
|
| Pulmonary Surfactant-Associated Protein A | 2 | 1998 | 32 | 0.050 |
Why?
|
| Reference Values | 3 | 1997 | 4982 | 0.040 |
Why?
|
| Receptors, CCR5 | 1 | 2002 | 497 | 0.040 |
Why?
|
| Breast Neoplasms | 4 | 2000 | 20822 | 0.040 |
Why?
|
| Prevalence | 2 | 2014 | 15226 | 0.040 |
Why?
|
| Social Control, Formal | 2 | 1998 | 110 | 0.040 |
Why?
|
| Drug Combinations | 2 | 2019 | 1959 | 0.040 |
Why?
|
| Drugs, Investigational | 1 | 2002 | 214 | 0.040 |
Why?
|
| Interleukin-12 | 1 | 2002 | 579 | 0.040 |
Why?
|
| Antigens, CD | 1 | 2010 | 4026 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2006 | 1836 | 0.040 |
Why?
|
| Leukopenia | 1 | 2000 | 212 | 0.040 |
Why?
|
| Ovulation | 1 | 1980 | 189 | 0.040 |
Why?
|
| Estrogens | 1 | 1986 | 1566 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2011 | 15076 | 0.040 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2002 | 615 | 0.040 |
Why?
|
| Hepatitis B, Chronic | 1 | 2003 | 393 | 0.040 |
Why?
|
| Gene Expression | 4 | 2000 | 7799 | 0.040 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2012 | 2988 | 0.040 |
Why?
|
| Prognosis | 4 | 2014 | 29063 | 0.040 |
Why?
|
| Galactosides | 1 | 1998 | 52 | 0.040 |
Why?
|
| Drug Resistance, Microbial | 1 | 2002 | 862 | 0.040 |
Why?
|
| Trimetrexate | 1 | 1998 | 15 | 0.040 |
Why?
|
| Empathy | 1 | 2003 | 474 | 0.040 |
Why?
|
| Intracranial Aneurysm | 1 | 2008 | 1197 | 0.040 |
Why?
|
| Fungal Vaccines | 1 | 1998 | 7 | 0.040 |
Why?
|
| Viremia | 2 | 1999 | 736 | 0.040 |
Why?
|
| Travel | 1 | 2005 | 788 | 0.040 |
Why?
|
| Prospective Studies | 5 | 2017 | 53288 | 0.040 |
Why?
|
| Eflornithine | 1 | 1998 | 31 | 0.040 |
Why?
|
| Epithelial Cells | 3 | 2015 | 3690 | 0.040 |
Why?
|
| Genes, gag | 1 | 1998 | 61 | 0.040 |
Why?
|
| Endocarditis, Bacterial | 1 | 1983 | 455 | 0.040 |
Why?
|
| Extracorporeal Circulation | 1 | 1998 | 182 | 0.040 |
Why?
|
| Constipation | 1 | 1983 | 546 | 0.040 |
Why?
|
| Pyrimethamine | 1 | 1998 | 97 | 0.040 |
Why?
|
| Liver Cirrhosis | 1 | 2008 | 1863 | 0.040 |
Why?
|
| Safety | 2 | 2000 | 1186 | 0.040 |
Why?
|
| Education, Medical, Graduate | 1 | 2010 | 2291 | 0.040 |
Why?
|
| Disease | 1 | 2003 | 680 | 0.040 |
Why?
|
| United States Food and Drug Administration | 2 | 2023 | 1584 | 0.040 |
Why?
|
| Peritonitis | 1 | 1999 | 365 | 0.040 |
Why?
|
| Interferon-gamma | 2 | 2005 | 3206 | 0.040 |
Why?
|
| Fibula | 1 | 1980 | 269 | 0.040 |
Why?
|
| Adolescent | 8 | 2009 | 85781 | 0.040 |
Why?
|
| Alcoholism | 1 | 2008 | 1906 | 0.040 |
Why?
|
| Quinoxalines | 1 | 2019 | 290 | 0.040 |
Why?
|
| Pyrrolidines | 1 | 2019 | 342 | 0.040 |
Why?
|
| Lymphocyte Activation | 2 | 2006 | 5524 | 0.040 |
Why?
|
| Macrolides | 1 | 1998 | 201 | 0.040 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2000 | 648 | 0.040 |
Why?
|
| Salvage Therapy | 1 | 2003 | 1275 | 0.040 |
Why?
|
| Puberty | 1 | 1980 | 490 | 0.040 |
Why?
|
| Receptors, Virus | 1 | 2000 | 648 | 0.040 |
Why?
|
| Curriculum | 1 | 2010 | 3605 | 0.040 |
Why?
|
| Tibial Fractures | 1 | 1980 | 269 | 0.040 |
Why?
|
| Gene Deletion | 1 | 2005 | 2751 | 0.040 |
Why?
|
| Voice Disorders | 1 | 2020 | 276 | 0.040 |
Why?
|
| MicroRNAs | 1 | 2012 | 3752 | 0.040 |
Why?
|
| Anti-HIV Agents | 2 | 2003 | 4256 | 0.040 |
Why?
|
| Rabbits | 1 | 2023 | 4894 | 0.040 |
Why?
|
| Cloning, Molecular | 2 | 2002 | 4320 | 0.040 |
Why?
|
| Aneurysm | 1 | 1980 | 339 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2012 | 9438 | 0.040 |
Why?
|
| Hydroxylation | 2 | 1986 | 141 | 0.040 |
Why?
|
| Epithelium | 2 | 1995 | 1679 | 0.030 |
Why?
|
| Adenoviridae | 1 | 2000 | 1099 | 0.030 |
Why?
|
| Leukocyte Count | 4 | 2004 | 1588 | 0.030 |
Why?
|
| Coronary Vessels | 1 | 1988 | 3107 | 0.030 |
Why?
|
| Estrogens, Catechol | 1 | 1995 | 25 | 0.030 |
Why?
|
| Recurrence | 4 | 2005 | 8340 | 0.030 |
Why?
|
| Cholic Acids | 1 | 1995 | 41 | 0.030 |
Why?
|
| 9,10-Dimethyl-1,2-benzanthracene | 1 | 1995 | 62 | 0.030 |
Why?
|
| Cholic Acid | 1 | 1995 | 34 | 0.030 |
Why?
|
| Blood Component Removal | 1 | 1997 | 125 | 0.030 |
Why?
|
| HLA-DR Antigens | 1 | 1997 | 645 | 0.030 |
Why?
|
| Lithocholic Acid | 1 | 1995 | 27 | 0.030 |
Why?
|
| Chenodeoxycholic Acid | 1 | 1995 | 34 | 0.030 |
Why?
|
| Ursodeoxycholic Acid | 1 | 1995 | 72 | 0.030 |
Why?
|
| Databases, Factual | 2 | 2007 | 7729 | 0.030 |
Why?
|
| Physarum polycephalum | 1 | 1994 | 2 | 0.030 |
Why?
|
| Hepatocytes | 1 | 2002 | 1211 | 0.030 |
Why?
|
| Child, Preschool | 5 | 2020 | 41006 | 0.030 |
Why?
|
| Causality | 1 | 2002 | 1275 | 0.030 |
Why?
|
| Internet | 1 | 2007 | 3064 | 0.030 |
Why?
|
| Waiting Lists | 1 | 2019 | 692 | 0.030 |
Why?
|
| Chromatography, Gas | 1 | 1994 | 156 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 3 | 2009 | 6386 | 0.030 |
Why?
|
| Fibrinolytic Agents | 1 | 2005 | 2158 | 0.030 |
Why?
|
| Leg | 1 | 1980 | 1116 | 0.030 |
Why?
|
| DNA | 1 | 1989 | 7301 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2002 | 4751 | 0.030 |
Why?
|
| Deglutition Disorders | 1 | 2020 | 605 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 2002 | 2216 | 0.030 |
Why?
|
| Research | 2 | 2017 | 1999 | 0.030 |
Why?
|
| Mycobacteriaceae | 1 | 1994 | 4 | 0.030 |
Why?
|
| Recombinant Proteins | 2 | 2002 | 6622 | 0.030 |
Why?
|
| Biopsy | 3 | 2008 | 6756 | 0.030 |
Why?
|
| Cell Adhesion | 3 | 1994 | 3144 | 0.030 |
Why?
|
| Blotting, Northern | 1 | 1996 | 1581 | 0.030 |
Why?
|
| Patient Selection | 2 | 2022 | 4215 | 0.030 |
Why?
|
| Transgenes | 1 | 1997 | 1009 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 2 | 1996 | 8301 | 0.030 |
Why?
|
| Mice, SCID | 2 | 2004 | 2716 | 0.030 |
Why?
|
| Benzimidazoles | 1 | 2019 | 850 | 0.030 |
Why?
|
| Teniposide | 1 | 1993 | 10 | 0.030 |
Why?
|
| Fleroxacin | 1 | 1993 | 13 | 0.030 |
Why?
|
| Phagocytosis | 2 | 1998 | 1539 | 0.030 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2004 | 1352 | 0.030 |
Why?
|
| Health Policy | 1 | 2006 | 2661 | 0.030 |
Why?
|
| Hepatitis B Core Antigens | 1 | 2014 | 92 | 0.030 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 1994 | 361 | 0.030 |
Why?
|
| Serial Passage | 1 | 1993 | 23 | 0.030 |
Why?
|
| Gene Transfer Techniques | 1 | 1999 | 1224 | 0.030 |
Why?
|
| Bone Marrow | 1 | 2004 | 2948 | 0.030 |
Why?
|
| Carcinogens | 1 | 1995 | 466 | 0.030 |
Why?
|
| Organ Culture Techniques | 1 | 1995 | 813 | 0.030 |
Why?
|
| Young Adult | 4 | 2019 | 56430 | 0.030 |
Why?
|
| Cytokines | 4 | 2012 | 7322 | 0.030 |
Why?
|
| Cells, Cultured | 4 | 2004 | 19229 | 0.030 |
Why?
|
| Leukapheresis | 1 | 2012 | 131 | 0.030 |
Why?
|
| Mice, Inbred Strains | 1 | 1995 | 1827 | 0.030 |
Why?
|
| Sinusitis | 1 | 2002 | 923 | 0.030 |
Why?
|
| Aspirin | 1 | 2005 | 3282 | 0.030 |
Why?
|
| Interleukin-2 | 1 | 2000 | 1904 | 0.030 |
Why?
|
| Patient Admission | 1 | 2020 | 1380 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2007 | 7722 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2003 | 2616 | 0.030 |
Why?
|
| Vaginal Smears | 1 | 1995 | 511 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2000 | 6314 | 0.030 |
Why?
|
| Macaca fascicularis | 1 | 2014 | 915 | 0.030 |
Why?
|
| Transfection | 1 | 2000 | 5892 | 0.030 |
Why?
|
| Immunotoxins | 1 | 2012 | 179 | 0.030 |
Why?
|
| Developing Countries | 1 | 2005 | 2815 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 1995 | 1799 | 0.030 |
Why?
|
| Decision Trees | 1 | 2014 | 506 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2003 | 19905 | 0.030 |
Why?
|
| Indium | 1 | 1991 | 46 | 0.020 |
Why?
|
| Technetium Tc 99m Aggregated Albumin | 1 | 1991 | 67 | 0.020 |
Why?
|
| Bone Neoplasms | 1 | 1984 | 2529 | 0.020 |
Why?
|
| Haplorhini | 2 | 1997 | 552 | 0.020 |
Why?
|
| European Union | 1 | 2012 | 158 | 0.020 |
Why?
|
| Premenopause | 1 | 1995 | 1033 | 0.020 |
Why?
|
| Health Education | 1 | 1998 | 1056 | 0.020 |
Why?
|
| Body Weight | 2 | 1989 | 4669 | 0.020 |
Why?
|
| Hospitalization | 2 | 2010 | 10262 | 0.020 |
Why?
|
| Thrombosis | 1 | 2005 | 2968 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1994 | 1572 | 0.020 |
Why?
|
| Smoking | 2 | 1989 | 8987 | 0.020 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2014 | 1155 | 0.020 |
Why?
|
| Gallium Radioisotopes | 1 | 1991 | 178 | 0.020 |
Why?
|
| Markov Chains | 1 | 2014 | 969 | 0.020 |
Why?
|
| Frontal Lobe | 1 | 1997 | 1406 | 0.020 |
Why?
|
| Cryptococcus | 1 | 2010 | 29 | 0.020 |
Why?
|
| Laminin | 1 | 1991 | 419 | 0.020 |
Why?
|
| Receptors, Opioid | 2 | 1983 | 155 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2019 | 1938 | 0.020 |
Why?
|
| Health Planning Guidelines | 1 | 2010 | 163 | 0.020 |
Why?
|
| Liver | 2 | 2006 | 7474 | 0.020 |
Why?
|
| Temporal Lobe | 1 | 1997 | 1670 | 0.020 |
Why?
|
| Aged, 80 and over | 4 | 2009 | 57776 | 0.020 |
Why?
|
| Fluorescence | 1 | 1991 | 751 | 0.020 |
Why?
|
| Blood Coagulation | 2 | 2009 | 1127 | 0.020 |
Why?
|
| Mucorales | 1 | 2009 | 33 | 0.020 |
Why?
|
| Follow-Up Studies | 6 | 2019 | 39050 | 0.020 |
Why?
|
| Specimen Handling | 1 | 1994 | 694 | 0.020 |
Why?
|
| Hemodynamics | 1 | 2019 | 4199 | 0.020 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 1989 | 212 | 0.020 |
Why?
|
| Lung Diseases, Parasitic | 1 | 1988 | 14 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2020 | 3778 | 0.020 |
Why?
|
| Immunologic Tests | 1 | 1989 | 103 | 0.020 |
Why?
|
| Major Histocompatibility Complex | 2 | 2004 | 936 | 0.020 |
Why?
|
| Killer Cells, Lymphokine-Activated | 1 | 2007 | 42 | 0.020 |
Why?
|
| Fibronectins | 1 | 1991 | 726 | 0.020 |
Why?
|
| Polyethylene Terephthalates | 1 | 1988 | 116 | 0.020 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 1989 | 370 | 0.020 |
Why?
|
| Antibodies, Protozoan | 1 | 1989 | 253 | 0.020 |
Why?
|
| Combined Modality Therapy | 3 | 2008 | 8642 | 0.020 |
Why?
|
| Complement Activation | 1 | 2009 | 453 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2008 | 35421 | 0.020 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2008 | 170 | 0.020 |
Why?
|
| Critical Illness | 1 | 2020 | 2670 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 1989 | 647 | 0.020 |
Why?
|
| Paranasal Sinus Diseases | 1 | 2008 | 116 | 0.020 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2014 | 1683 | 0.020 |
Why?
|
| Massachusetts | 1 | 2020 | 8663 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 1995 | 2187 | 0.020 |
Why?
|
| Phylogeny | 1 | 1994 | 2803 | 0.020 |
Why?
|
| Disease Notification | 1 | 2007 | 97 | 0.020 |
Why?
|
| Temporal Arteries | 1 | 2008 | 128 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1989 | 1375 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2010 | 20129 | 0.020 |
Why?
|
| Pneumonia, Pneumococcal | 1 | 1988 | 127 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2020 | 3679 | 0.020 |
Why?
|
| Infarction | 1 | 2008 | 244 | 0.020 |
Why?
|
| Cross Reactions | 1 | 1989 | 841 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 1998 | 4803 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2000 | 11366 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 1991 | 2031 | 0.020 |
Why?
|
| Renal Circulation | 1 | 2007 | 333 | 0.020 |
Why?
|
| Dexamethasone | 2 | 1991 | 1951 | 0.020 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 1989 | 768 | 0.020 |
Why?
|
| Proteinuria | 1 | 2009 | 658 | 0.020 |
Why?
|
| Menopause | 2 | 1986 | 1626 | 0.020 |
Why?
|
| Gene Knockout Techniques | 1 | 2009 | 809 | 0.020 |
Why?
|
| Granzymes | 1 | 2008 | 271 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2020 | 5317 | 0.020 |
Why?
|
| Lipopeptides | 1 | 2006 | 75 | 0.020 |
Why?
|
| Pregnenolone | 1 | 1986 | 26 | 0.020 |
Why?
|
| Mammary Tumor Virus, Mouse | 1 | 1986 | 61 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2015 | 4204 | 0.020 |
Why?
|
| Los Angeles | 1 | 2006 | 238 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2009 | 1866 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2019 | 8324 | 0.020 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2002 | 3523 | 0.020 |
Why?
|
| Diagnosis-Related Groups | 1 | 2007 | 455 | 0.020 |
Why?
|
| Apoptosis | 1 | 2002 | 9727 | 0.020 |
Why?
|
| Haplotypes | 2 | 2004 | 2779 | 0.020 |
Why?
|
| Chromosomes | 1 | 1989 | 596 | 0.020 |
Why?
|
| Pan troglodytes | 1 | 1986 | 229 | 0.020 |
Why?
|
| Myocardium | 3 | 2004 | 4776 | 0.020 |
Why?
|
| Dihydrotestosterone | 1 | 1986 | 190 | 0.020 |
Why?
|
| Immunoblotting | 1 | 1989 | 1682 | 0.020 |
Why?
|
| North America | 1 | 2009 | 1249 | 0.020 |
Why?
|
| Resource Allocation | 1 | 2007 | 341 | 0.020 |
Why?
|
| Pediatrics | 1 | 2020 | 3475 | 0.020 |
Why?
|
| Ethics Committees, Research | 1 | 2006 | 194 | 0.020 |
Why?
|
| Glucosamine | 1 | 1985 | 132 | 0.020 |
Why?
|
| Serum Albumin, Bovine | 1 | 2005 | 324 | 0.020 |
Why?
|
| Receptors, Complement | 1 | 2005 | 264 | 0.020 |
Why?
|
| Optic Nerve | 1 | 2008 | 554 | 0.020 |
Why?
|
| Public Health | 1 | 1998 | 2603 | 0.020 |
Why?
|
| Mice, Inbred C3H | 1 | 1986 | 964 | 0.020 |
Why?
|
| Coronary Circulation | 2 | 2007 | 1572 | 0.020 |
Why?
|
| Blotting, Western | 2 | 1989 | 5179 | 0.010 |
Why?
|
| Giant Cell Arteritis | 1 | 2008 | 292 | 0.010 |
Why?
|
| Drug Resistance, Fungal | 1 | 2003 | 52 | 0.010 |
Why?
|
| Membrane Lipids | 1 | 1985 | 248 | 0.010 |
Why?
|
| Cohort Studies | 2 | 2014 | 40561 | 0.010 |
Why?
|
| Antigens | 1 | 2009 | 1466 | 0.010 |
Why?
|
| Disease Progression | 1 | 2020 | 13284 | 0.010 |
Why?
|
| Leucine | 1 | 1985 | 561 | 0.010 |
Why?
|
| Magnesium Chloride | 1 | 2002 | 32 | 0.010 |
Why?
|
| Manganese Compounds | 1 | 2002 | 27 | 0.010 |
Why?
|
| Ribonuclease H | 1 | 2002 | 45 | 0.010 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1985 | 964 | 0.010 |
Why?
|
| Immunoglobulin M | 2 | 1998 | 1537 | 0.010 |
Why?
|
| Dementia | 1 | 1997 | 2518 | 0.010 |
Why?
|
| New England | 1 | 2006 | 1022 | 0.010 |
Why?
|
| Consensus | 1 | 2012 | 2959 | 0.010 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2003 | 424 | 0.010 |
Why?
|
| Microcirculation | 1 | 2007 | 1286 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 2006 | 2645 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 15540 | 0.010 |
Why?
|
| Cricetinae | 1 | 2006 | 2472 | 0.010 |
Why?
|
| Biotransformation | 1 | 1982 | 168 | 0.010 |
Why?
|
| Hematocrit | 1 | 2003 | 636 | 0.010 |
Why?
|
| Primary Prevention | 1 | 1989 | 1167 | 0.010 |
Why?
|
| Interleukin-4 | 1 | 2005 | 1147 | 0.010 |
Why?
|
| Klebsiella Infections | 1 | 1983 | 138 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 2006 | 1677 | 0.010 |
Why?
|
| Progesterone | 1 | 1986 | 776 | 0.010 |
Why?
|
| Vision Disorders | 1 | 2008 | 1058 | 0.010 |
Why?
|
| Brain | 4 | 2008 | 26385 | 0.010 |
Why?
|
| Palatine Tonsil | 1 | 2001 | 193 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2004 | 2505 | 0.010 |
Why?
|
| Headache | 1 | 2008 | 1226 | 0.010 |
Why?
|
| Sodium Chloride | 1 | 2002 | 625 | 0.010 |
Why?
|
| Homeodomain Proteins | 1 | 2009 | 2421 | 0.010 |
Why?
|
| Chlorides | 1 | 2002 | 667 | 0.010 |
Why?
|
| Adenosine | 1 | 1985 | 825 | 0.010 |
Why?
|
| Drug Approval | 1 | 2006 | 742 | 0.010 |
Why?
|
| Mice, Inbred NOD | 1 | 2004 | 1878 | 0.010 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 2002 | 486 | 0.010 |
Why?
|
| Equipment Design | 1 | 1988 | 3582 | 0.010 |
Why?
|
| Canada | 1 | 2005 | 2065 | 0.010 |
Why?
|
| Fractures, Closed | 1 | 1980 | 88 | 0.010 |
Why?
|
| Dancing | 1 | 1980 | 101 | 0.010 |
Why?
|
| Macrophages | 1 | 1994 | 5655 | 0.010 |
Why?
|
| Immunosorbent Techniques | 1 | 1998 | 184 | 0.010 |
Why?
|
| Streptococcal Infections | 1 | 1983 | 638 | 0.010 |
Why?
|
| Placebos | 1 | 1983 | 1676 | 0.010 |
Why?
|
| Journalism, Medical | 1 | 1998 | 74 | 0.010 |
Why?
|
| Molecular Structure | 1 | 2002 | 1899 | 0.010 |
Why?
|
| Hypertension | 2 | 1989 | 8480 | 0.010 |
Why?
|
| Edetic Acid | 1 | 1998 | 276 | 0.010 |
Why?
|
| Animal Experimentation | 1 | 1998 | 45 | 0.010 |
Why?
|
| Ethics | 1 | 1998 | 94 | 0.010 |
Why?
|
| Hybrid Cells | 1 | 1997 | 441 | 0.010 |
Why?
|
| Endorphins | 1 | 1977 | 75 | 0.010 |
Why?
|
| Hemoperfusion | 1 | 1997 | 14 | 0.010 |
Why?
|
| Hydrolases | 1 | 1998 | 139 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2004 | 2649 | 0.010 |
Why?
|
| Hemoglobins | 1 | 2003 | 1534 | 0.010 |
Why?
|
| Chromatography, Affinity | 1 | 1998 | 549 | 0.010 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 1997 | 517 | 0.010 |
Why?
|
| Enkephalins | 1 | 1977 | 154 | 0.010 |
Why?
|
| Concanavalin A | 1 | 1997 | 191 | 0.010 |
Why?
|
| Guideline Adherence | 1 | 2007 | 2266 | 0.010 |
Why?
|
| Splenectomy | 1 | 1998 | 395 | 0.010 |
Why?
|
| Discriminant Analysis | 1 | 1997 | 235 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2007 | 6538 | 0.010 |
Why?
|
| Thinness | 1 | 1980 | 480 | 0.010 |
Why?
|
| Amenorrhea | 1 | 1980 | 485 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 1982 | 2187 | 0.010 |
Why?
|
| Infant | 2 | 2009 | 35136 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2001 | 2256 | 0.010 |
Why?
|
| ABO Blood-Group System | 1 | 1998 | 367 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2009 | 10252 | 0.010 |
Why?
|
| Ureter | 1 | 1999 | 375 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 2001 | 1880 | 0.010 |
Why?
|
| Colon | 1 | 1984 | 1772 | 0.010 |
Why?
|
| Alzheimer Disease | 1 | 1997 | 8037 | 0.010 |
Why?
|
| Brain Damage, Chronic | 1 | 1976 | 265 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 1991 | 14722 | 0.010 |
Why?
|
| Transcription Factors | 1 | 1995 | 12208 | 0.010 |
Why?
|
| Intelligence Tests | 1 | 1976 | 505 | 0.010 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2000 | 652 | 0.010 |
Why?
|
| Lymphoid Tissue | 1 | 1997 | 455 | 0.010 |
Why?
|
| Testosterone | 1 | 1986 | 2420 | 0.010 |
Why?
|
| Candida albicans | 1 | 1998 | 394 | 0.010 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 1998 | 1369 | 0.010 |
Why?
|
| Antigens, Viral | 1 | 1998 | 1035 | 0.010 |
Why?
|
| Transduction, Genetic | 1 | 1997 | 913 | 0.010 |
Why?
|
| Isoantigens | 1 | 1997 | 567 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 1999 | 2124 | 0.010 |
Why?
|
| Angiography | 1 | 1980 | 1639 | 0.010 |
Why?
|
| Kinetics | 1 | 1982 | 6473 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2007 | 3444 | 0.010 |
Why?
|
| Logistic Models | 1 | 2009 | 13408 | 0.010 |
Why?
|
| Isoantibodies | 1 | 1997 | 679 | 0.010 |
Why?
|
| Random Allocation | 2 | 1989 | 2429 | 0.010 |
Why?
|
| Skin Transplantation | 1 | 1999 | 1074 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2004 | 5974 | 0.010 |
Why?
|
| Staphylococcal Infections | 1 | 1983 | 1400 | 0.010 |
Why?
|
| Antigen-Presenting Cells | 1 | 1997 | 973 | 0.010 |
Why?
|
| Sodium | 2 | 1989 | 1623 | 0.010 |
Why?
|
| Uncertainty | 1 | 1998 | 734 | 0.010 |
Why?
|
| Diet | 1 | 1991 | 7939 | 0.010 |
Why?
|
| Quality of Health Care | 1 | 2007 | 4371 | 0.010 |
Why?
|
| Epitopes | 1 | 1999 | 2571 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2004 | 9734 | 0.010 |
Why?
|
| Fluorometry | 1 | 1991 | 106 | 0.010 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 1991 | 225 | 0.010 |
Why?
|
| Guidelines as Topic | 1 | 1998 | 1405 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2005 | 14557 | 0.010 |
Why?
|
| Mice, Nude | 1 | 1997 | 3689 | 0.010 |
Why?
|
| Glycoproteins | 1 | 1998 | 2263 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 1994 | 1263 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2001 | 3474 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2000 | 6895 | 0.010 |
Why?
|
| Fetus | 1 | 1997 | 1880 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2009 | 25625 | 0.010 |
Why?
|
| Age Factors | 1 | 1986 | 18370 | 0.010 |
Why?
|
| Chronic Disease | 1 | 1983 | 9146 | 0.000 |
Why?
|
| Natriuresis | 1 | 1987 | 124 | 0.000 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 1997 | 6038 | 0.000 |
Why?
|
| Alcohol Drinking | 2 | 1989 | 3966 | 0.000 |
Why?
|
| Potassium | 1 | 1989 | 1336 | 0.000 |
Why?
|
| Antigens, Surface | 1 | 1989 | 1663 | 0.000 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 1997 | 4386 | 0.000 |
Why?
|
| Interleukin-6 | 1 | 1994 | 3200 | 0.000 |
Why?
|
| Diet, Reducing | 1 | 1987 | 462 | 0.000 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1994 | 4420 | 0.000 |
Why?
|
| Trachea | 1 | 1988 | 1076 | 0.000 |
Why?
|
| Monitoring, Physiologic | 1 | 1989 | 1738 | 0.000 |
Why?
|
| Cardiac Surgical Procedures | 1 | 1976 | 3537 | 0.000 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 1962 | 648 | 0.000 |
Why?
|
| Pituitary Gland | 1 | 1962 | 665 | 0.000 |
Why?
|
| Cell Differentiation | 1 | 1997 | 11483 | 0.000 |
Why?
|
| Exercise Test | 1 | 1987 | 2074 | 0.000 |
Why?
|
| Allyl Compounds | 1 | 1977 | 23 | 0.000 |
Why?
|
| Life Style | 1 | 1989 | 3835 | 0.000 |
Why?
|
| Tachyphylaxis | 1 | 1977 | 51 | 0.000 |
Why?
|
| Antihypertensive Agents | 1 | 1987 | 2046 | 0.000 |
Why?
|
| Algorithms | 1 | 1997 | 13881 | 0.000 |
Why?
|
| Guinea Pigs | 1 | 1977 | 1386 | 0.000 |
Why?
|
| Coronary Angiography | 1 | 1987 | 4577 | 0.000 |
Why?
|
| Muscle, Smooth | 1 | 1977 | 934 | 0.000 |
Why?
|
| Exercise | 1 | 1989 | 5615 | 0.000 |
Why?
|
| Muscle Contraction | 1 | 1977 | 1240 | 0.000 |
Why?
|
| Heart Valve Prosthesis | 1 | 1976 | 1488 | 0.000 |
Why?
|
| Coronary Artery Bypass | 1 | 1976 | 2289 | 0.000 |
Why?
|
| Suicide | 1 | 1976 | 1477 | 0.000 |
Why?
|
| Delirium | 1 | 1976 | 1609 | 0.000 |
Why?
|